Anticancer fusion protein
AssigneeAdamed Sp. z o.o.
InventorsJerzy Szczepan Pieczykolan, Krzysztof Kazimierz Lemke, Sebastian Pawlak, Bartlomiej Zerek
Life of this patent
Estimating the term…
Abstract
A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and domain (b) which is a sequence of an immunostimulating effector peptide, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases.
Claims23
A fusion protein comprising:
- domain (a) which is a functional fragment of hTRAIL protein having the sequence set forth as SEQ. No. 16, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity;
- and
- domain (b) which is an immunostimulating effector peptide,
- wherein domain (b) is attached at the C-terminus or N-terminus of domain (a).
(canceled)
12-18. (canceled)
20-21. (canceled)
A method of treatment of cancer diseases in a mammal, including human, comprising administration to the mammal in a need thereof of an anti-cancer effective amount of the fusion protein as defined.
Dependencies are inferred from the claim text.